Ocular Therapeutix, Inc. is a fully-integrated biopharmaceutical company. AXPAXLI, the Company's investigational product candidate for retinal disease, is an axitinib intravitreal hydrogel based on its ELUTYX bioresorbable hydrogel-based formulation technology. Its pipeline also leverages the ELUTYX technology in its commercial product DEXTENZA, a corticosteroid for the treatment of ocular inflammation and pain following ophthalmic surgery in adults and pediatric patients, and ocular itching associated with allergic conjunctivitis in adults and pediatric patients aged two years or older, and in its investigational product candidate PAXTRAVA, which is a travoprost intracameral hydrogel for the treatment of open-angle glaucoma or ocular hypertension. The ELUTYX technology provides delivery solutions for durable therapies for wet age-related macular degeneration (wet AMD), NPDR, DME, proliferative diabetic retinopathy, retinal vein occlusion, and other diseases and conditions of the eye.
Growing
The company is in a growing phase, with the latest annual income totaling USD 51.95M.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 51.95M.
Fairly Valued
The company’s latest PE is -6.59, at a medium 3-year percentile range.
Institutional Buying
The latest institutional holdings are 212.47M shares, increasing 5.74% quarter-over-quarter.
Held by Steven Cohen
Star Investor Steven Cohen holds 5.49M shares of this stock.